Evidence map›Paper›PMID 27999015›Full record

ArticleThe Journal of antimicrobial chemotherapy2017

A single dose of epidermicin NI01 is sufficient to eradicate MRSA from the nares of cotton rats.

Samantha Halliwell, Peter Warn, Abdul Sattar, Jeremy P Derrick, Mathew Upton

Open access · hybridAbstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Epidermicin NI01 demonstrates potentJAC-antimicrobial resistance · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Towards sustainable antimicrobial therapies forSustainable microbiology · 2024
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Discovery ofMicroorganisms · 2021
    Article
  11. Virulence Factors in Coagulase-Negative Staphylococci.Pathogens (Basel, Switzerland) · 2021
    Review
  12. Frontiers in microbiology · 2021
    Review
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Samantha HalliwellFaculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Peter WarnFaculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Abdul SattarEvotec (UK) Ltd, Manchester Science Park, Manchester, UK.
Jeremy P DerrickFaculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Mathew UptonFaculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
University of Manchester · GBEvotec (United Kingdom) · GBPeninsula College of Medicine and Dentistry · GB

Funding

Biotechnology and Biological Sciences Research Council BB/J021474/1
6 · The paper itself

Abstract

Objectives: To investigate the efficacy of a potent novel antimicrobial protein of mass 6 kDa, epidermicin NI01, for eradicating the nasal burden of MRSA in a cotton rat ( Sigmodon hispidus ) model. Methods: MRSA strain ATCC 43300 was used to establish a robust colonization of cotton rat nares. This model was used to evaluate the efficacy of topical 0.04% and 0.2% epidermicin NI01, administered twice daily for 3 days consecutively, and topical 0.8% epidermicin NI01 administered once, for reducing nasal MRSA burden. Control groups remained untreated or were administered vehicle only (0.5% hydroxypropylmethylcellulose) or 2% mupirocin twice daily for 3 days. The experiment was terminated at day 5 and MRSA quantitative counts were determined. Tissues recovered from animals treated with 0.2% epidermicin twice daily for 3 days were examined for histological changes. Results: Mupirocin treatment resulted in a reduction in burden of log 10 (log R) of 2.59 cfu/nares compared with vehicle ( P  < 0.0001). Epidermicin NI01 administered once at 0.8% showed excellent efficacy, resulting in a log R of 2.10 cfu/nares ( P  = 0.0004), which was equivalent to mupirocin. Epidermicin NI01 administered at 0.2% or 0.04% twice daily for 3 days did not have a significant impact on the tissue burden recovered from the nares. Mild to marked histological abnormalities were noted, but these were determined to be reversible. Conclusion: A single dose of topical epidermicin NI01 was as effective as mupirocin administered twice daily for 3 days in eradication of MRSA from the nares of cotton rats. This justifies further development of epidermicin for this indication.

Indexed as

Administration, TopicalAnimalsAntimicrobial Cationic PeptidesBacterial LoadBacteriocinsDose-Response Relationship, DrugMethicillin-Resistant Staphylococcus aureusMupirocinNoseRatsSigmodontinaeStaphylococcal InfectionsAntimicrobial Cationic PeptidesBacteriocinsepidermicin NI01, Staphylococcus epidermidisMupirocin

Identifiers

PMID27999015
PMCPMC5400076
OpenAlexW2566325112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.